After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
Executive Summary
Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.
You may also be interested in...
Finance Watch: Early-Stage Firms Gain Deal-Making Insight As Golumbeski Joins VC Ranks
Private Company Edition: Celgene's former top deal-maker George Golumbeski is now a life science business consultant and venture partner at ARCH. Also, a VC investment surge portends another big year for biopharma, including $85m for Ansun and $66m for FogPharma.
What Takeda's Failed TOMMORROW Trial Means For Early Alzheimer's Today
The TOMMORROW study was revolutionary for its time in testing Actos early, before symptoms are apparent; failure is disappointing but similar metabolic approaches might still play a role, says the Alzheimer's Association.
Alzheimer's Prevention: The Next Big Idea For Fixing Drug Trial Failures
Mass screening of asymptomatic people is an expensive, daunting proposition, but very preliminary research with an amyloid beta blood test is spurring hope that a more practical way to identify those at risk will emerge in the future.